iTeos Therapeutics Has Dosed First Patient In GALAXIES Lung-301 Phase 3 Trial Of Belrestotug+Dostarlimab Vs. Placebo+Pembrolizumab For First-line Advanced, Unresectable, Or Metastatic PD-L1 High Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
iTeos Therapeutics has dosed the first patient in its Phase 3 trial of Belrestotug+Dostarlimab for advanced non-small cell lung cancer, triggering a $35 million milestone payment from GSK. The companies have a collaboration agreement for the development and commercialization of belrestotug.
July 08, 2024 | 11:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK has made a $35 million milestone payment to iTeos Therapeutics following the dosing of the first patient in a Phase 3 trial for advanced lung cancer. This payment is part of a broader collaboration agreement for the development and commercialization of belrestotug.
The milestone payment underscores GSK's commitment to the collaboration with iTeos and the potential of belrestotug. This progress in the clinical trial could positively impact GSK's oncology portfolio.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
iTeos Therapeutics has dosed the first patient in its Phase 3 trial for advanced lung cancer, triggering a $35 million milestone payment from GSK. This milestone is part of a larger collaboration agreement with GSK, which includes significant upfront and potential milestone payments.
The dosing of the first patient in a Phase 3 trial is a significant milestone for iTeos, indicating progress in their clinical development. The $35 million payment from GSK provides additional financial resources and validates the ongoing collaboration.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100